In partnership with Harvard Medical School spin-off, Aramis Biosciences, Exscalate was used to rapidly identify a lead compound for the previous unmet need of an effective treatment for Dry Eye Disease. The project progressed from zero to Phase II investigational new drug approval in just 14 months.